Prof. Mark Lowdell Explains How INKmune Arms Natural Killer Cells to Kill Solid Tumors

Dr. Mark Lowdell, CSO of INmune Bio gave a plenary talk on October 17, 2022 at the Innate Killer Summit, London to explain how INKmune arms Natural Killer (NK) to override immunosuppression in an active Tumor Microenvironment (TME) to kill solid tumors.

The interaction of the TME with cancer cells and immune cells can drive tumor progression and prevent many cell therapies from being effective. These complex interactions should be considered when designing cell therapies to treat solid tumors. In solid tumors, the TME is hostile to cell therapies because of (i) the presence of immunosuppressive immunoregulatory cells, and (ii) the low levels of oxygen (hypoxia). A cell therapy must operate in this hostile environment to successfully treat solid tumors.

INKmune converts patient’s normal resting NK (rNK) cells into potent memory-like NK cells that target solid tumors directly, even in the presence of immunosuppressive immunoregulatory cells and hypoxia associated with the TME. The Company’s pre-clinical data show that INKmune primes NK cells from patients and from healthy donors to lyse NK-resistant ovarian (CaOva), prostate (CaPros), renal (RCC) and nasopharyngeal (NPC) cancer cells. When compared to rNK cells, which are normal NK cells from healthy donors or patients before treatment with INKmune, the INKmune primed NK cells demonstrated enhanced ability to kill these resistant tumor cell lines.

#oncology #cancer #cancertreatment #ovariancancer #kidneycancer #prostatecancer #INKmune #INMB #clinicaltrials #biotechnology #biotech #biotechstocks #healthcare #naturalkillercells